Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Key Sessions

Pernille Tofteng Shelton

Identification of Long Acting, GIP/GLP-1 Dual Acting Peptide Hormones

Zealand Pharma, Denmark

Alice Gaudin

Development Of Liposomal Formulations For Intracellular Delivery Of Therapeutic Peptides

IPSEN Innovation

08:00 - 09:00 60 mins
09:00 - 09:10 10 mins
Chairperson's Opening Remarks
  • Waleed Danho - Distinguished Research Leader and Consultant for Peptides, Danho Associates Inc, USA
09:10 - 09:50 40 mins
Identification of Long Acting, GIP/GLP-1 Dual Acting Peptide Hormones
  • Pernille Tofteng Shelton - Senior Scientist, Zealand Pharma, Denmark
09:50 - 10:30 40 mins
HER-2 B Cell Epitope Peptide-Based Cancer Vaccines and Combination Immunotherapies with EGFR, HER-3, IGF-1R, VEGF and a PD-1 Vaccine
  • Pravin Kaumaya - Professor, Vaccine Development/Peptide & Protein Engineering Laboratory, The Ohio State University Wexner Medical Center and the James Hospital and Comprehensive Cancer Center

We have created and established a pipeline/ portfolio of validated B-cell peptide vaccines (HER-2, HER-3, HER-1, VEGF, IGF-1R and PD-1) against multiple receptor tyrosine kinases (RTK’s) to expedite the development of new paradigm shifting cancer immune-therapies.

We have translated two HER-2 B-cell epitopes peptide vaccines comprising epitopes designed to mimic the trastuzumab and pertuzumab binding epitopes to the clinic in an NCI-funded and FDA approved Phase 1/2b trial (NCT01376505). This presentation will detail our clinical trial and basic studies based on the development of combinatorial immunotherapeutic strategies that act synergistically to enhance immune-mediated tumor killing aimed at addressing mechanisms of tumor resistance for several tumor types.

10:30 - 11:30 60 mins
Morning Coffee and Networking
11:30 - 12:10 40 mins
Exenatide and Its Life Cycle
  • Christopher Rhodes, Ph.D. - President and CEO, Drug Delivery Experts
12:10 - 12:50 40 mins
Development Of Liposomal Formulations For Intracellular Delivery Of Therapeutic Peptides
  • Alice Gaudin - Senior Scientist, IPSEN Innovation

Despite numerous intracellular therapeutic opportunities, less than 10% of peptides entering clinical trials have intracellular targets, due to inherent limitations such as poor cellular penetration and lysosomal degradation. With several formulations already on the market, liposomes have emerged as leading candidates for drug delivery, thanks to their versatility in terms of API formulation and therapeutic applications. Using a microfluidics platform, we developed several liposomal formulations of therapeutic peptides and investigated their intracellular entry. We demonstrated the possibility to efficiently load therapeutic peptides into liposomes, allowing effective delivery to tumor cells.

12:50 - 14:00 70 mins
14:00 - 14:40 40 mins
Overview Of The Status And Challenges Associated With Delivery Of Therapeutic Peptides To Improve Dosing Regimen (Extended PK/Half-Life) And Minimally Invasive Delivery
  • Pradeep Dhal - Senior R&D Director, Sanofi Global R&D, Genzyme Corporation - A Sanofi Company
14:40 - 15:20 40 mins
Tailoring Peptides For Less Frequent Dosing By Endowing Them To Selectively Bind To Transthyretin
  • Mamoun Alhamadsheh - Associate Professor of Pharmaceutical Chemistry, University of the Pacific

Peptides hold great potential as anticancer agents. However, a major challenge impeding the widespread use of peptides is their poor pharmacokinetic profile, due to short circulation half-life. In this talk I will discuss our effort in developing a fundamentally new approach for enhancing the circulation half-life of peptides without affecting its biological potency.

15:20 - 16:00 40 mins
Afternoon Coffee
16:00 - 16:40 40 mins
Industry Case Study: Delivery Strategies For Targeting The Lymphatic System
  • Yves Decadt - Chief Executive Officer, BioLingus
  • Case study examples on sublingual delivery of peptides
16:40 - 17:20 40 mins
N-Butylpyrrolidone as a Green Solvent for SPPS
  • John Lopez - Peptide Synthesis Expert, Novartis AG

With the main goal of finding a green solvent that could be used in the large scale manufacture of peptide be the SPPS methodology. A set of candidate green solvents were tested for their feasibility of replacing reprotoxic DMF, our results indicates that N-Butylpyrrolidone (NBP) can be used as a green solvent for SPPS. In this presentation I will show our results and share our view for further development in the direction of a greener peptide synthesis.

17:20 - 19:00 100 mins
Drinks Reception in Exhibition Hall
19:00 - 22:00 180 mins
Coaches depart for Networking Dinner (you must collect your wristband during the Monring Coffee Break)